Author:
Alimena G,Breccia M,Mancini M,Ferranti G,De Felice L,Gallucci C,Mandelli F
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference10 articles.
1. Andersen MK, Pedersen-Bjergaard J, Kjeldsen L, Dufva IH, Brondum-Nielsen K . Clonal Ph− negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8. Leukemia 2002; 16: 1390–1395.
2. Braziel RM, Launder TM, Druker BJ, Olson SB, Magenis RE, Mauro MJ et al. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. Blood 2002; 100: 435–441.
3. Chee YL, Vickers MA, Stevenson D, Holyoake TL, Culligan DJ . Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones. Leukemia 2003; 17: 634–635.
4. Marktel S, Marin D, Foot N, Szydlo R, Bua M, Karadimitris A et al. Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression. Haematologica 2003; 88: 260–267.
5. Meeus P, Demuynck H, Martiat P, Michaux L, Wouters E, Hagemeijer A . Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with imatinib. Leukemia 2003; 17: 465–467.
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献